Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5085897 | 0.93 | ACE2 (0.36) | DNM1OPRM1ACE2ALDH1A1TDP1 | |
| SCHEMBL1109998 | 0.93 | OPRM1 (0.42) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL27492754 | 0.91 | ACE2 (0.44) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL28154825 | 0.91 | ACE2 (0.44) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL28271641 | 0.91 | ACE2 (0.44) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL9207452 | 0.91 | ACE2 (0.44) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL28153725 | 0.91 | ACE2 (0.44) | DNM1OPRM1ACE2LMNATSHR | |
| SCHEMBL22032613 | 0.87 | — | — | |
| SCHEMBL42281 | 0.87 | — | — | |
| SCHEMBL10415869 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4180041-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11596629-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-12-29 | — | — | US | disclosed |
| US-11325892-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-10 | — | — | US | disclosed |
| EP-3808349-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3177292-B1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3194371-B1 | ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS | AGENCY SCIENCE TECH & RES (SG) | 2020-09-02 | — | — | EP | disclosed |
| CN-107108518-B | Antibacterial imidazolium compounds | 新加坡科技研究局 | 2020-08-11 | — | — | CN | disclosed |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2020-02-27 | — | — | US | disclosed |
| CN-1009554-B | RHIZOXIN DERIVATIVES AND ITS PROCESS FOR PREPARING THE SAME | SANKYO CO (JP) | 1990-09-12 | — | — | CN | disclosed |
| CN-1042153-A | 3-aryloxy methyl-cephalosporins derivatives, their preparation and purposes pharmaceutically | SANKYO CO (JP) | 1990-05-16 | — | — | CN | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| CN-1040982-A | Nitragin (rhizoxin) derivative and as antineoplastic agent | SANKYO CO (JP) | 1990-04-04 | — | — | CN | disclosed |
| CN-1040196-A | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | SANKYO CO (JP) | 1990-03-07 | — | — | CN | disclosed |
| EP-0353047-A2 | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4791128-A | Rhizoxin esters and salts, their pharmaceutical use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1988-12-13 | — | — | US | disclosed |
| EP-0218310-A2 | Rhizoxin derivatives, their preparation and pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-04-15 | — | — | EP | disclosed |
| CN-86102020-A | The preparation method of rhizoxin derivatives and in pharmaceutically application | — | 1986-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325892-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | DNM1 728/4885OPRM1 1999/4885ACE2 2754/4885 |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | DNM1 728/4885OPRM1 1999/4885ACE2 2754/4885 |
| US-11596629-B2 | Compounds and methods for treating cancer | SCD, SCD5, CPT1B | DNM1 1277/4885OPRM1 3654/4885ACE2 2351/4885 |
| US-20200061055-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | DNM1 1277/4885OPRM1 3654/4885ACE2 2351/4885 |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | DNM1 1277/4885OPRM1 3654/4885ACE2 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.